Pharmafile Logo

Free Thinking: From promise to practice: immuno-oncology in action

January 6, 2016 | immuno-oncology, immunotherapy 

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. 

Immuno-oncology therapies that harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.

Clinical trials of emerging products, both alone and in combination, have delivered impressive evidence of improvements in durability and endpoints such as progression-free survival, and even overall survival. R&D pipelines are stuffed with immuno-oncology prospects across a wide range of indications.

To date, only a few immuno-oncology products have actually reached the market though. Two of them target the anti-PD1/PD-L1 pathway where much of the interest in immuno-oncology is currently invested.

Download and read part 1 of the complimentary whitepaper at:
http://www.researchpartnership.com/news/2015/11/free-thinking-from-promise-to-practice-immuno-oncolo…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Forever Angels founder is awarded an MBE

We are delighted to announce that Forever Angels founder Amy Hathaway has been awarded an MBE in this year’s Queen’s Birthday Honours list for providing interim and community care to...

Research Partnership’s Singapore team relocates to new office

We are delighted to announce that our Asia-Pacific team in Singapore has relocated to new premises.

Nutrition Market in Brazil: Growth Against the Odds

Published in eyeforpharma June 2017 by Marc Yates

Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report

Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership is celebrating 20 years in business

Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus...

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership announces several new appointments

Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.

PMRC San Francisco 2017

We are delighted to be presenting a paper and exhibiting at the Pharmaceutical Market Research Conference 13-14 June in Bay Area close to our new office in San Francisco.Representing Research...

EphMRA Annual Conference 2017

Visit us on stand number 14

Richard Head nominated for EphMRA Award

We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been...